Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent, Nascent in Antibody Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Catalent, Nascent in Antibody Development Pact

Will use GPEx technology to express brain cancer treatment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions and Nascent Biologics have signed a product development agreement in which Catalent will engineer a cell line expressing Nascent’s proprietary pritumumab antibody using Catalent’s GPEx technology, and will subsequently produce purified monoclonal antibody to support Nascent’s Phase I/II human clinical trials with pritumumab for treatment of brain cancers, such as astrocytomas and glioblastomas.

GPEx technology is used to generate mammalian cells with high yields and stability, which will help speed the drug to clinic.

Mark Glassy, Ph.D., CEO of Nascent, observed, “We are committed to bring this potential new treatment to patients afflicted with this terrible disease. Our first clinical data are very encouraging and we look forward to working with Catalent to gather the key clinical data that will enable further development to be ‘fast tracked’ with relevant regulatory agencies on a worldwide basis. Nascent Biologics is in the process of forming a commercial partnership for further clinical development, registration, and marketing of its Pritumumab product.” Pritumumab’s early trials showed a ninefold increase in five-year survival rates.

“We are delighted to be part of a program that will not only validate our GPEx technology as a leading system for the manufacture of biologic products, but will also aid in significantly improving the treatment outcomes for such a serious and untreatable disease,” said Kent Payne, vice president and general manager of Catalent’s Biologics business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics